

Supplement 1-Search strategy for included Databases

Database: Embase Classic+Embase <1947 to 2021 March 19>

Search Strategy:

-
- 1 immune related adverse events.mp. (4239)
 - 2 (immun* adj3 checkpoint adj3 (inhibitor* or modulator* or antibod* or block*)).ti,rn. (6657)
 - 3 ipilimumab.ti,rn. (15258)
 - 4 Tremelimumab.ti,rn. (341)
 - 5 anti-CTLA-4.ti,rn. (426)
 - 6 cytotoxic T-lymphocyte associated antigen-4.ti,rn. (173)
 - 7 nivolumab.ti,rn. (20844)
 - 8 pembrolizumab.ti,rn. (18583)
 - 9 anti-PD-1.ti,rn. (2362)
 - 10 programmed cell death protein.ti,rn. (248)
 - 11 atezolizumab.ti,rn. (6605)
 - 12 avelumab.ti,rn. (2944)
 - 13 durvalumab.ti,rn. (4633)
 - 14 cemiplimab.ti,rn. (456)
 - 15 anti-PD-L1.ti,rn. (687)
 - 16 programmed cell death protein-1.ti,rn. (192)
 - 17 programmed cell death-Ligand 1.ti,rn. (440)
 - 18 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (45834)
 - 19 toxicit*.ti,rn. (122683)
 - 20 1 or 19 (126583)
 - 21 18 and 20 (3872)

Database: Ovid MEDLINE: Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE® Daily and Ovid MEDLINE® <1946-Present>

Search Strategy:

-
- 1 immune related adverse events.mp. (2497)
 - 2 (immun* adj3 checkpoint adj3 (inhibitor* or modulator* or antibod* or block*).ti,rn. (3980)
 - 3 ipilimumab.ti,rn. (2487)
 - 4 Tremelimumab.ti,rn. (187)
 - 5 anti-CTLA-4.ti,rn. (218)
 - 6 cytotoxic T-lymphocyte associated antigen-4.ti,rn. (146)
 - 7 nivolumab.ti,rn. (3924)
 - 8 pembrolizumab.ti,rn. (2979)
 - 9 anti-PD-1.ti,rn. (1071)
 - 10 programmed cell death protein.ti,rn. (197)
 - 11 atezolizumab.ti,rn. (763)
 - 12 avelumab.ti,rn. (269)
 - 13 durvalumab.ti,rn. (374)
 - 14 cemiplimab.ti,rn. (53)
 - 15 anti-PD-L1.ti,rn. (291)
 - 16 programmed cell death protein-1.ti,rn. (152)
 - 17 programmed cell death-Ligand 1.ti,rn. (303)
 - 18 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (13870)
 - 19 toxicit*.ti,rn. (90322)
 - 20 1 or 19 (92625)
 - 21 18 and 20 (1926)
